Haemophilus influenzae type b vaccine was licensed in the United States in the spring of 1985. Prior to licensure, extensive data had accumulated, indicating that this vaccine was safe and was immunogenic in children >18 to 23 months of age. Furthermore, in a large efficacy trial conducted in Finland, the vaccine also was found to be approximately 80% protective in preventing invasive type b Haemophilus disease in children 24 to 35 months of age (95% confidence interval 8, 95).1,2 Unfortunately, it was ineffective in children <18 months of age, the group most susceptible to Haemophilus disease, and it was of uncertain efficacy in those 18 to 23 months of age.
Skip Nav Destination
Commentary| October 01 1987
Safety and Efficacy of Haemophilus influenzae Type b Polysaccharide Vaccine
Pediatrics (1987) 80 (4): 590–592.
- Views Icon Views
- Share Icon Share
- Search Site
DAN M. GRANOFF, MICHAEL T. OSTERHOLM; Safety and Efficacy of Haemophilus influenzae Type b Polysaccharide Vaccine. Pediatrics October 1987; 80 (4): 590–592. 10.1542/peds.80.4.590
Download citation file: